Quel est le prix pour AlloVir, Inc. (ALVR)

Le prix pour AlloVir, Inc. (ALVR) est $9.81

Quelle est la capitalisation boursière pour AlloVir, Inc. (ALVR)

La capitalisation boursière pour AlloVir, Inc. (ALVR) est $48.68M

AlloVir, Inc. (ALVR) Historique des Prix

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Année	Performance
2025	-11.26%
2024	-74.50%
2023	-70.35%
2022	-60.21%
2021	-61.81%
2020	0.00%

Année

Performance

2025

-11.26%

2024

-74.50%

2023

-70.35%

2022

-60.21%

2021

-61.81%

2020

0.00%

Entreprise	Prix de l'action	Variation 1a%	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$539.14	35.65%	US
Argenx SE ARGX.US	$1.04K	56.21%	NL
CSL Limited CSL.AX	$118.33	-18.49%	AU
Lonza Group AG LONN.SW	$761.87	8.65%	CH
Moderna, Inc. MRNA.US	$130.43	397.46%	US

Entreprise

Prix de l'action

Variation 1a%

Pays